Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemafibrate - Kowa Pharmaceutical

Drug Profile

Pemafibrate - Kowa Pharmaceutical

Alternative Names: K 877; K-877 CR; K-877 IR; K-877-BC; K-877-ER; K-877-FL; Parmodia

Latest Information Update: 23 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kowa Pharmaceutical
  • Developer Jaeb Center for Health Research; Kowa Pharmaceutical
  • Class Antihyperlipidaemics; Benzoxazoles; Butyric acids; Fibric acid derivatives; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia
  • Phase III Diabetic retinopathy; Dyslipidaemias; Hypertriglyceridaemia
  • Phase II Non-alcoholic fatty liver disease
  • No development reported Primary biliary cirrhosis

Most Recent Events

  • 27 May 2021 Kowa Pharmaceutical expects the approval for Hypertriglyceridaemia from the US FDA in mid-2023
  • 20 Apr 2021 Kowa Pharmaceuticals files phase III approval studies in Dyslipidaemias in Singapore and Malaysia (Kowa Pharmaceuticals, April 2021)
  • 20 Apr 2021 Kowa Pharmaceuticals plans phase III approval studies in Dyslipidaemias in Malaysia and Singapore (Kowa Pharmaceuticals, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top